CAH Stock Analysis — Cardinal Health
Sector: Healthcare Distribution
AI Verdict
Cardinal Health trades at 19.4x next year's earnings with nearly 50% EPS growth expected—cheap for the growth you're getting if its distribution moat continues to deliver, especially with the stock now technically oversold.
Competitive Moat
Cardinal Health operates one of the largest pharmaceutical and medical supply distribution networks in the U.S., making it a critical link between manufacturers and thousands of healthcare providers. Its scale and entrenched logistics relationships create high switching costs for hospitals and pharmacies, defending its market share.
Summary
RSI at 29.3 signals the stock is oversold despite a 50% one-year return and forward EPS growth expected at 48.5%.
Where It Stands
Cardinal Health has delivered a 227% five-year return, trades at 19.4x forward earnings versus the healthcare sector's 22x median, and shows an oversold RSI of 29.3.
Key Metrics
- RSI: 29.3 — Oversold
- Trailing P/E: 28.8x
- Forward P/E: 19.4x
- PEG Ratio: 0.61
- Earnings Growth: +0.5%
- Revenue Growth: +0.1%
- Market Cap: $47.2B
- 1-Year Return: 50.01%
- 5-Year Return: 227%
Bull Case
With analysts forecasting 48.5% EPS growth and a forward P/E of 19.4x, you're paying less than the sector average for much faster earnings acceleration.
Bear Case
If the P/E reverts to the sector median of 22x from its current 28.8x trailing level, shares could see a valuation-driven pullback unless growth materializes as forecast.
Catalyst to Watch
Watch for quarterly earnings to confirm whether the 48.5% EPS growth materializes, as any miss could quickly erase the recent 50% one-year gain.